Mechanism of inhibition of human secretory phospholipase A2 by flavonoids: rationale for lead design.
The human secretory phospholipase A2 group IIA (PLA2-IIA) is a lipolytic enzyme. Its inhibition leads to a decrease in eicosanoids levels and, thereby, to reduced inflammation. Therefore, PLA2-IIA is of high pharmacological interest in treatment of chronic diseases such as asthma and rheumatoid arthritis. Quercetin and naringenin, amongst other flavonoids, are known for their anti-inflammatory activity by modulation of enzymes of the arachidonic acid cascade. However, the mechanism by which flavonoids inhibit Phospholipase A2 (PLA2) remained unclear so far. Flavonoids are widely produced in plant tissues and, thereby, suitable targets for pharmaceutical extractions and chemical syntheses. Our work focuses on understanding the binding modes of flavonoids to PLA2, their inhibition mechanism and the rationale to modify them to obtain potent and specific inhibitors. Our computational and experimental studies focused on a set of 24 compounds including natural flavonoids and naringenin-based derivatives. Experimental results on PLA2-inhibition showed good inhibitory activity for quercetin, kaempferol, and galangin, but relatively poor for naringenin. Several naringenin derivatives were synthesized and tested for affinity and inhibitory activity improvement. 6-(1,1-dimethylallyl)naringenin revealed comparable PLA2 inhibition to quercetin-like compounds. We characterized the binding mode of these compounds and the determinants for their affinity, selectivity, and inhibitory potency. Based on our results, we suggest C(6) as the most promising position of the flavonoid scaffold to introduce chemical modifications to improve affinity, selectivity, and inhibition of PLA2-IIA by flavonoids.
Lättig
Jens
J
Structural Bioinformatics, BIOTEC TU Dresden, Tatzberg 47-51, 01307, Dresden, Germany. jens.laettig@biotec.tu-dresden.de
Böhl
Markus
M
Fischer
Petra
P
Tischer
Sandra
S
Tietböhl
Claudia
C
Menschikowski
Mario
M
Gutzeit
Herwig O
HO
Metz
Peter
P
Pisabarro
M Teresa
MT
D020134:Catalytic Domain; D003198:Computer Simulation; D017076:Computer-Aided Design; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology*; D005419:Flavonoids / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology*; D006801:Humans; D008024:Ligands; D008958:Models, Molecular; D054497:Phospholipases A2, Secretory / Q000037:antagonists & inhibitors* / Q000737:chemistry; D013816:Thermodynamics
D004791:Enzyme Inhibitors; D005419:Flavonoids; D008024:Ligands; D054497:Phospholipases A2, Secretory
Nat Struct Biol. 2000 Sep;7(9):786-91
10966651
Nucleic Acids Res. 2000 Jan 1;28(1):235-42
10592235
Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):16625-30
12486225
Inflammation. 1997 Jun;21(3):347-56
9246576
Chembiochem. 2003 Mar 3;4(2-3):181-5
12616631
J Med Chem. 1994 Feb 4;37(3):337-41
8308860
J Med Chem. 1992 Aug 7;35(16):2939-51
1501221
Biochemistry. 2002 Dec 17;41(50):14790-800
12475227
Biochim Biophys Acta. 2005 Apr 15;1733(2-3):157-71
15863363
Nat Struct Biol. 1999 Aug;6(8):775-84
10426957
J Mol Graph. 1996 Feb;14(1):33-8, 27-8
8744570
J Med Chem. 1995 Jul 7;38(14 ):2681-91
7629807
Curr Opin Biotechnol. 1995 Dec;6(6):646-51
8527834
FASEB J. 1991 Apr;5(7):2068-77
1901288
Acta Crystallogr B. 2002 Jun;58(Pt 3 Pt 1):380-8
12037359
Biochem Biophys Res Commun. 1994 Nov 30;205(1):843-9
7999121
Life Sci. 1994;54(20):PL333-8
8190018
Mol Cell. 2000 Oct;6(4):909-19
11090628
Nat Struct Biol. 1995 Jun;2(6):458-65
7664108
Biochem Pharmacol. 2004 Apr 15;67(8):1607-17
15041478
Org Biomol Chem. 2005 Sep 7;3(17 ):3117-26
16106293
J Thromb Haemost. 2005 Feb;3(2):369-76
15670046
Methods Mol Biol. 2004;284:229-42
15173620
Anal Biochem. 2006 Dec 15;359(2):280-2
17045950